Who We Are / Leading the Way in Biohazardous Waste Recycling / Envetec

Envetec is an Irish company with a global vision to create clean change. Our mission is to assist all laboratories to achieve their sustainability goals.

Envetec was founded in 2021 as a spin-out from Technopath Clinical Diagnostics, a leader in clinical diagnostics, whose clients included global diagnostic companies and clinical laboratories. Envetec’s GENERATIONS® – our clean technology – represents 10 years of investment in research and development combined with industry collaboration to deliver the best solution for the safe treatment of laboratory biohazardous waste while becoming the essential link in the chain to enable single use plastic recycling.

One day all waste will be treated this way.

Envetec is disruptive. Our team comes from pharma, diagnostics, sport, business, technology, media, science and financial services.

With such widespread experience one would expect conflict but what has been achieved is a relentless curiosity. There is another way, a different way, a better way. We are a R&D Cleantech company building sustainable solutions to reduce CO2 emissions and enable the circular economy, replacing current unsustainable practices. There is no longer a reason to continue to cook, bury and burn valuable resources. There is a better way, the Envetec way.

Meet the Team
The people who
make it all happen

Envetec has built an experienced team with a tangible track record of success. At its core is a passion for excellence, a drive for innovation and a mission to make a real difference. GENERATIONS is not just the name of our technology; it is a central tenet of our philosophy.

What can we learn from past generations, what can the younger generations teach us about the world they want to live in and how can we leave a beneficial legacy for future generations? Our Board has chaired or directed sector appropriate businesses in the past, our executives have delivered at the highest levels of performance and our team has the energy and curiosity to learn from the past to deliver for the future.

Leadership team

Malcolm Bell

Chief Executive Officer

Malcolm Bell serves as Chief Executive Officer of Envetec Sustainable Technologies.... read more

Malcolm Bell serves as Chief Executive Officer of Envetec Sustainable Technologies, Ireland's first cleantech company focused on breakthrough innovations to treat and repurpose biohazardous waste materials on-site, significantly reducing dependency on landfills, incineration and autoclaving. Addressing the growing urgency to achieve a substantive path toward net-zero from the diagnostic, healthcare, and food and beverage industries, Malcolm established Envetec as a standalone business in 2021. Based on extensive R&D investment, the company is poised to transform the management of biohazardous, biomedical and regulated medical waste, introducing first-in-class environmentally friendly technologies.

In 2004, Malcolm co-founded Technopath Clinical Diagnostics, a global leader in developing and manufacturing innovative quality control (QC) solutions for clinical laboratories used in 125 countries. He served as CEO and oversaw the successful acquisition of the company to LGC in 2020.
Malcolm has a track record of creating significant value by advancing assets, intellectual property, technology, and product portfolios. In 2014, he spun out two companies from Technopath - ValitaCell Ltd and Oculer Ltd, respectively. Both spin-offs have allowed each company to commercialize disruptive technologies spanning drug discovery and development, food quality, food safety, and environmental monitoring applications.

Most recently, Malcolm consulted for New York's largest healthcare provider, Northwell Health, by being appointed President & CEO of Northwell Holdings and Ventures, the for-profit organization of the hospital network. Within 12 months, he created a five-year strategic roadmap to support critical funding initiatives, including evaluating the Health System's existing investment portfolio, investment companies, and joint ventures alongside introducing a new operating model and organizational structure.

Malcolm earned his undergraduate degree in molecular biology and his master's degree in biotechnology from the National University of Ireland.

Peter Thornton

President and Chief Financial Officer

Peter Thornton is President, Chief Financial Officer and a founder of Envetec... read more

Peter Thornton is President, Chief Financial Officer and a founder of Envetec. Peter brings significant experience in corporate finance, business development and financial management in both public and private life science companies. Peter is a non-executive director of Avadel Pharmaceuticals plc, a NASDAQ listed biopharmaceutical company, and Oculer Limited, a company developing and commercialising proprietary rapid microbiology technology. Previously, he was CFO of Technopath Clinical Diagnostics (until its sale to LGC Group in 2021), a provider of quality control solutions to clinical laboratories worldwide.
Prior roles include SVP Corporate Development for Northwell Health, a leading US healthcare system; SVP Business Integration for Alkermes plc, a global biopharmaceuticals company; SVP Business and Product Development for Elan Corporation plc’s drug delivery division; President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical company; and CFO of Agenus Inc, a NASDAQ listed immuno-oncology biotechnology company.

Peter has served as a non-executive director of both public and private companies including Leon-Nanodrugs GmbH, Valitacell Limited, Merrion Pharmaceuticals plc, Cydex Pharmaceuticals Inc. and Antigenics Inc. Peter worked for the international public accounting firm of KPMG in Ireland and France and is a fellow of Chartered Accountants Ireland and a member of the Institute of Directors. He holds a Bachelor of Commerce degree from University College Cork, Ireland.

Keith Wood

Head of Corporate Development

Keith Wood is Head of Corporate Development at Envetec... read more

Keith Wood is Head of Corporate Development at Envetec. He established W2 over 25 years ago, creating a group of businesses that support marketing & strategic planning, leadership development, client acquisition. W2 is a blend of his experience in international sport, broadcasting and business, built on an understanding of success and failure in high performing teams and individuals. Investor wise, Keith has followed his interests, from media to property, from sports science to rural regeneration, from healthy ageing to lifestyle businesses.

Keith captained the Irish Rugby Team 36 times, toured with the Lions twice, and is the inaugural winner of the World Player of the Year in 2001. Keith has worked extensively in journalism and media, writing for The Times, The Daily Telegraph, and Independent News as well as broadcasting for the BBC and Newstalk. He Chaired Spin South West and was Director of Communicorp Media until its sale in 2021 and is an Honorary Adjunct Professor for Sports Journalism at the University of Limerick.

He has been active in the public service and charity sectors advocating for closer links with key stakeholders and building relationships within and between different communities. Keith is an Honorary Fellow Of the Royal College of Surgeons for his Role as Chair of the Healthy Ireland Council and holds an Honorary Doctor of Science from UL for services to Sport and Community. In addition, he is a Patron of both the Special Olympics and the UNESCO Chair for Inclusive Physical Education, Sport, Recreation, and Fitness in Tralee IT.

Sunny Uberoi

Head of Communications and Public Affairs

Sunny is a seasoned communications strategist who has worked in senior roles across diverse sectors... read more

Sunny is a seasoned communications strategist who has worked in senior roles across diverse sectors, including healthcare, financial services, technology, and consumer. Sunny has been advising CEOS of several startup companies specialising in gene therapy, type 2 diabetes, biohazardous waste, diagnostics, immuno-oncology, and organ transplantation from IPO readiness, advocacy, media to regulatory communications.

Sunny also served as the global head of communications for S&P Global Market Intelligence, Pfizer Consumer Healthcare, BMS, Agenus and Elan as well as holding various pharmaceutical industry marketing positions.

Sunny graduated with honors from Manchester Metropolitan University (Economics) and has a master’s in marketing from Manchester Business School.

Guy McDonnell

Chief Operating Officer

Guy is the Chief Operating Officer at Envetec and brings extensive operations and engineering leadership experience in the global biotech sector to this role. ... read more

Guy is the Chief Operating Officer at Envetec and brings extensive operations and engineering leadership experience in the global biotech sector to this role. During a career spanning over 20 years at Pfizer, Guy led the startup of several biotech manufacturing organizations, including a $500M Gene Therapy facility in North Carolina. His tenure offered firsthand insight into the challenges confronting the biopharma industry due to the widespread adoption of single-use plastics.

Moreover, Guy led the Engineering and EHS team of Pfizer’s largest integrated biotechnology facility, which supported the manufacture of over $7 billion in global sales. In his recent role as a senior leader within Pfizer’s Global Corporate Engineering team, Guy managed engineering operations across 14 sterile filling sites spanning the US, Europe, and Asia.

Guy holds an MBA from the Michael Smurfit Business School (University College Dublin) and Bachelor's and Master's degrees in Mechanical Engineering from Trinity College Dublin.

Paul Woodstock

President of Envetec USA

Paul has been a Healthcare leader in the US for over 20 years, he has held executive leadership roles as VP of Human Resources... read more

Paul has been a Healthcare leader in the US for over 20 years, he has held executive leadership roles as VP of Human Resources, Sr. VP of Marketing, Divisional VP of Sales; and Executive VP of Sales and Marketing. Paul is passionate about building and developing teams of talented individuals who are focused on finding solutions for customers.

In addition to working for large medical device companies such as St. Jude Medical and Biotronik, Paul has consulted, invested in and worked for, many start up organizations. He has spent the past two years as a Partner at Muir Sustainability helping healthcare systems and Fortune 500 companies reduce their carbon footprint to achieve their net zero goals.

Paul is a graduate of the University of Maine with a BA in Journalism. He is also a graduate of the Harvard Business School.

Paul Coyne

VP of Business Development (Industry)

Paul Coyne is Vice President of Business Development for Envetec. Envetec is an Irish company with a global vision to create clean change. ... read more

Paul Coyne is Vice President of Business Development for Envetec. Envetec is an Irish company with a global vision to create clean change.

Paul gained his BSC from UCD and moved from University to roles covering both Laboratory and QA with the Kerry Group. Following this he joined Technopath Distribution in 2005 as a Technical Sales representative and ultimately covered roles of increasing responsibility before becoming Business Development Manager. In 2015 Paul joined IDEXX Laboratories where he was Sales Manager for Europe and various Distribution territories. His experience includes Pharma, Med-Device ,Food And Beverage as well as extensive knowledge of the Veterinary sector.

Paul is passionate about creating clean change and is confident that we can have positive environmental impact by responsible treatment of Laboratory Biohazardous waste.

Conor Connolly

VP of Business Development (IVD)

Conor Connolly is Vice President of Business Development for Envetec. Envetec is an Irish company with a global vision to create clean change. Their mission is to enable all laboratories to move towards zero biohazardous waste.

Conor has an honours Degree in Biotechnology from DCU and moved from University in to a role in a microbiology laboratory in Icon plc. Following this he joined Technopath Clinical Diagnostics in 2011. Conor was VP of Commercial for Technopath, managing all global sales, marketing and business development teams. Following the acquisition of Technopath by LGC in 2021, Conor became VP of Global Sales for all LGC clinical diagnostic business.

Board of Directors

Imogen Joss

Chair

Imogen spent her executive career in the fintech arena as Commercial Director of the London Stock Exchange and latterly President of two divisions of S&P Global. ... read more

Imogen spent her executive career in the fintech arena as Commercial Director of the London Stock Exchange and latterly President of two divisions of S&P Global. She brings global experience to the boards that she serves plus a strong commercial, client and talent-focused agenda while specialising in Remuneration Committee work on both listed and non-listed boards.

She currently serves on the boards of five organisations across advisory services, fintech and cleantech including as Chair of Grant Thornton UK llp and SID at Fintel plc.

As well as mentoring a number of CEOs and senior leaders, as Chair of Trustees of a charity focused on the alleviation of rural child poverty in the UK, Imogen and her team support those at the sharp end of delivering education, health care and social support.